$ARNA Arena Pharmaceuticals Inc. Company Overview
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on discovery, development and commercialization of drugs in the therapeutic areas such as cardiovascular, central nervous system, inflammatory and metabolic diseases. Its product pipeline includes Lorcaserin, APD811, APD334, APD371, GPR119 agonists, temanogrel and nelotanserin. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.
ARNA Last Price: 6.55
Last Updated: November 29, 2013 2:14 PM EST
ARNA Stock Message Board and Forum http://investorshangout.com/search?q=ARNA&...mp;yt0=Go!
Arena Pharmaceuticals Inc. ARNA Officers and Executives
Name Age Officer Since Title
Mr. Jack Lief 67 1997 Chairman, President & Chief Executive Officer
Dr. Craig M. Audet 49 2011 SVP-Operations & Head-Global Regulatory Affairs
Mr. Robert E. Hoffman 47 1997 Chief Financial Officer & Vice President
Dr. William R. Shanahan 64 2004 Chief Medical Officer & Senior Vice President
Dr. Dominic P. Behan 49 1997 Chief Scientific Officer, Executive Director & EVP
Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego, California 92121
Phone
1 8584537200
Industry
Biotechnology
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$27.59M
Net Income
$-85.48M
2012 Sales Growth
116.9%
Employees
293.00
Annual Report Below for ARNA
Arena Pharmaceuticals Inc. ARNA Recent Headlines
MarketWatch News on ARNA
Arena shares surge as marketer doubles sales force for diet drug 11:41 a.m. Oct. 15, 2013 - Russ Britt
Obesity drug makers jockey for position as analysts praise Vivus 12:06 p.m. Oct. 3, 2013 - Russ Britt
Hedge funds are buying these stocks right now 1:46 p.m. July 23, 2013 - Insider Monkey
5 stocks insiders are buying 1:52 p.m. June 7, 2013 - Insider Monkey
6 gut checks before the stock market's opening bell 6:47 a.m. March 7, 2013 - Shawn Langlois
Stocks to watch Monday: Transocean, Stratasys 9:22 a.m. March 4, 2013 - Sue Chang
Arena Pharmaceuticals down 7.4% in premarket 9:11 a.m. Jan. 22, 2013 - Steve Gelsi
What 2012’s winners and losers say about 2013 6:00 a.m. Dec. 14, 2012 - Howard Gold
6 gut checks before the stock market's opening bell 6:50 a.m. Dec. 12, 2012 - Shawn Langlois
4 charts challenging resistance 7:06 a.m. Oct. 16, 2012 - The Trading Deck
Vivus sees EU regulators rejecting diet drug 12:16 p.m. Sept. 21, 2012 - MarketWatch.com
Vivus falls 11% on EU drug approval update 11:07 a.m. Sept. 21, 2012 - Val Brickates Kennedy
Arena rises as Vivus sees anti-obesity setback 7:49 a.m. Sept. 21, 2012 - Greg Morcroft
Vivus says Europe likely to reject obesity drug 7:33 a.m. Sept. 21, 2012 - MarketWatch.com
Orexigen soars 19% on analyst buy rating 12:46 p.m. Sept. 6, 2012 - Val Brickates Kennedy
Arena jumps 12% amid takeover speculation 1:55 p.m. Aug. 14, 2012 - Val Brickates Kennedy
Arena trips Nasdaq short-sale circuit breaker 3:01 p.m. Aug. 1, 2012 - Val Brickates Kennedy
Arena Pharma share drop trips short-sale limit 2:16 p.m. Aug. 1, 2012 - Laura Mandaro
Eisai gears up for launch of Arena's diet drug 9:32 a.m. July 30, 2012 - Val Brickates Kennedy
Apple, Arena active; Lumber Liquidators at new high 9:06 a.m. July 25, 2012 - blogs.marketwatch.com
Contrave Data is Positive for Orexigen's Other Weight-Loss Candidate - Analyst 1:08 p.m. Nov. 27, 2013 - Seeking Alpha
ARNA January 2014 Options Begin Trading 10:53 a.m. Nov. 27, 2013 - TheStreet.com
Orexigen Sees Positive Interim Results On Drug Study 1:18 a.m. Nov. 26, 2013 - Seeking Alpha
Arena's Belviq Prescription Data - Week 23 1:28 p.m. Nov. 25, 2013 - Seeking Alpha
Orexigen to Seek FDA Approval for Contrave 12:43 p.m. Nov. 25, 2013 - WSJ.com
3 Monday Morning Biotech Movers 12:15 p.m. Nov. 25, 2013 - Wall St. Cheat Sheet
Investors Put Greater Weight Behind Orexigen Than Arena, Vivus 12:10 p.m. Nov. 25, 2013 - TheStreet.com
Orexigen Weight-Loss Pill Passes Safety Hurdle 7:41 a.m. Nov. 25, 2013 - TheStreet.com
December 27th Options Now Available For Arena Pharmaceuticals (ARNA) 11:02 a.m. Nov. 21, 2013 - TheStreet.com
Interesting ARNA Put And Call Options For July 2014 12:02 p.m. Nov. 19, 2013 - TheStreet.com
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results 1:11 p.m. Nov. 16, 2013 - GuruFocus.com
Apple’s Smartphone Share Declines, JPMorgan’s Chinese Debacle, and 3 More Hot Stocks 1:08 p.m. Nov. 15, 2013 - Wall St. Cheat Sheet
Benzinga's Top #PreMarket Gainers 7:16 a.m. Nov. 15, 2013 - benzinga.com
ARNA December 13th Options Begin Trading 10:53 a.m. Nov. 14, 2013 - TheStreet.com
Arena Expands Marketing Of Obesity Drug To Help Shrink Waistlines 5:00 p.m. Nov. 12, 2013 - TheStreet.com
10-Q: ARENA PHARMACEUTICALS INC 3:52 p.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Jim Cramer: Buy Apple, Sell AMD, and 2 More Stock Picks 12:05 p.m. Nov. 12, 2013 - Wall St. Cheat Sheet
Arena Pharmaceuticals (ARNA) Worth a Look: Stock Surges 10.6% - Tale of the Tape 8:44 a.m. Nov. 12, 2013 - Zacks.com
Cramer's Lightning Round - Don't Back Away From The Hottest Stock In The Universe (11/11/13) 6:03 a.m. Nov. 12, 2013 - Seeking Alpha
'Mad Money' Lightning Round: 6:00 a.m. Nov. 12, 2013 - TheStreet.com
Press Releases on ARNA
Promising Partnerships, Stock Price Updates and Participation in Upcoming Healthcare Conferences - Research Report on Quest Diagnostics, Cigna, Arena, Theravance, and Volcano 8:00 a.m. Today - PR Newswire
Arena Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference 8:00 a.m. Nov. 27, 2013 - PR Newswire
Trend Analysis Scan: Synovus Financial, Arena Pharmaceuticals, Facebook Inc, J.C. Penney Company, Citigroup 8:49 a.m. Nov. 26, 2013 - PR Newswire
Early Briefing and Review: Arena Pharma Inc., Geron Corp., Incyte Corp., and Spectrum Pharma Inc. 1:31 p.m. Nov. 22, 2013 - PR Newswire
Health Care Initiatives, Clinical Data Presentations, Public Offerings, Contract Extensions and Publication of Pre-Clinical Study - Research Report on Cigna, Arena, Synta, Healthways, and Catalyst 8:00 a.m. Nov. 21, 2013 - PR Newswire
BELVIQ® (lorcaserin HCl) CIV Data to be Presented at American Heart Association 2013 Scientific Sessions 8:00 a.m. Nov. 18, 2013 - PR Newswire
BELVIQ® (lorcaserin HCl) CIV Data Featured in Five Abstracts to be Presented at ObesityWeek(SM) 2013 4:05 p.m. Nov. 13, 2013 - PR Newswire
Biotechnology Companies' Quarterly Results - Research Report on Geron, Santarus, Merrimack, Clovis, and Arena 8:00 a.m. Nov. 12, 2013 - PR Newswire
GOGO, CLDX, VPHM and ARNA Added to NASDAQ Active Stock Watch List at EPR 10:14 a.m. Nov. 11, 2013 - ACCESSWIRE
TrendingWallStreet.com Initiates Research on EGY, GLER, PGLO, and ARNA 12:16 a.m. Nov. 11, 2013 - ACCESSWIRE
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results 4:10 p.m. Nov. 7, 2013 - PR Newswire
Arena Pharmaceuticals and Eisai Expand Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) to Include Most Countries Worldwide 4:02 p.m. Nov. 7, 2013 - PR Newswire
FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on Pfizer, Mettler-Toledo, Arena, Wright Medical, and Ophthotech 8:00 a.m. Nov. 7, 2013 - PR Newswire
Must Watch Stock News: Arena Pharmaceuticals, Hewlett-Packard Company, Resorts International, Alpha Natural Resources, Chevron Corporation 1:56 p.m. Nov. 4, 2013 - PR Newswire
Pre-Market Review: Arena Pharma Inc., Geron Corp., Incyte Corp. Ltd, and Spectrum Pharma Inc. 9:00 a.m. Oct. 31, 2013 - PR Newswire
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7 8:00 a.m. Oct. 30, 2013 - PR Newswire
Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics, Halozyme, Insmed, and Omeros 8:00 a.m. Oct. 21, 2013 - PR Newswire
Arena Pharmaceuticals Reports That Eisai Will Double BELVIQ® (lorcaserin HCl) CIV Sales Force by December 9:03 a.m. Oct. 15, 2013 - PR Newswire
Early Briefing and Review: Arena Pharma Inc., Spectrum Pharma Inc., Incyte Corp. Ltd., and Geron Corp. 9:26 a.m. Oct. 8, 2013 - PR Newswire
Drug Approvals, Data Presentations, Conferences, Increased Funding, and Merger Agreements - Research Report on Theravance, Arena, Exelixis, Verenium, and Enanta 8:00 a.m. Sept. 25, 2013 - PR Newswire
Valuation
P/E Current
-14.31
P/E Ratio (with extraordinary items)
-81.48
Price to Sales Ratio
64.26
Price to Book Ratio
19.89
Enterprise Value to EBITDA
-25.27
Enterprise Value to Sales
15.59
Total Debt to Enterprise Value
0.04
Efficiency
Revenue/Employee
0.09
Income Per Employee
-0.29
Receivables Turnover
8.95
Total Asset Turnover
0.13
Liquidity
Current Ratio
5.72
Quick Ratio
5.52
Cash Ratio
5.22
Profitability
Gross Margin
-34.55
Operating Margin
-207.03
Pretax Margin
-309.85
Net Margin
-309.85
Return on Assets
-40.87
Return on Equity
-156.55
Return on Total Capital
-62.36
Return on Invested Capital
-63.05
Capital Structure
Total Debt to Total Equity
75.49
Total Debt to Total Capital
43.02
Total Debt to Total Assets
28.51
Long-Term Debt to Equity
73.80
Long-Term Debt to Total Capital
42.05
Arena Pharmaceuticals Inc. ARNA Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 9.81M 10.39M 16.61M 12.72M 27.59M
Cost of Goods Sold (COGS) incl. D&A 22.49M 21.06M 19.97M 19.22M 37.12M
COGS excluding D&A 8.52M 6.54M 7.41M 8.1M 27.37M
Depreciation & Amortization Expense 13.98M 14.53M 12.55M 11.12M 9.75M
Depreciation 11.67M 11.02M 10.39M 10.13M 9.06M
Amortization of Intangibles 2.31M 3.51M 2.16M 997,000 691,000
Gross Income (12.69M) (10.68M) (3.35M) (6.51M) (9.53M)
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 223.24M 124.39M 93M 72.83M 47.58M
Research & Development 204.37M 110.16M 75.46M 58.71M 30.41M
Other SG&A 18.87M 14.23M 17.54M 14.12M 17.17M
Other Operating Expense 0 0 0 0 0
Unusual Expense 3.84M 385,000 7.98M 13.93M 19.76M
EBIT after Unusual Expense (3.84M) (385,000) (7.98M) (13.93M) (19.76M)
Non Operating Income/Expense (1.1M) 273,000 1.02M (1.77M) 400,000
Non-Operating Interest Income 8.97M 689,000 469,000 117,000 119,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 5.68M 18.72M 21.68M 14.31M 9.12M
Gross Interest Expense 5.68M 18.72M 21.68M 14.31M 9.12M
Interest Capitalized 0 0 0 0 0
Pretax Income (237.57M) (153.2M) (124.53M) (109.22M) (85.48M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 -
Income Tax - Current Foreign 0 0 0 0 -
Income Tax - Deferred Domestic 0 0 0 0 -
Income Tax - Deferred Foreign 0 0 0 0 -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (237.57M) (153.2M) (124.53M) (109.22M) (85.48M)
Minority Interest Expense 0 0 0 0 0
Net Income (237.57M) (153.2M) (124.53M) (109.22M) (85.48M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (237.57M) (153.2M) (124.53M) (109.22M) (85.48M)
Preferred Dividends 1.91M 0 0 2.26M 2.82M
Net Income Available to Common (239.49M) (153.2M) (124.53M) (111.48M) (88.3M)
EPS (Basic) (3.24) (1.82) (1.14) (0.80) (0.45)
Basic Shares Outstanding 73.84M 84.34M 109.57M 139.17M 196.52M
EPS (Diluted) (3.24) (1.82) (1.14) (0.80) (0.45)
Diluted Shares Outstanding 73.84M 84.34M 109.57M 139.17M 196.52M
EBITDA (221.95M) (120.54M) (83.8M) (68.21M) (47.37M)
Arena Pharmaceuticals Inc. ARNA Filings
SEC Filings for Arena Pharmaceuticals Inc.
Filing Date Document Date Type Category Amended
11/12/2013 09/30/2013 10-Q Quarterly Reports
11/08/2013 11/07/2013 8-K Special Events
11/07/2013 11/07/2013 8-K Special Events
10/15/2013 10/15/2013 8-K Special Events
08/29/2013 08/28/2013 8-K Special Events
08/28/2013 08/28/2013 8-K Special Events
08/05/2013 06/30/2013 10-Q Quarterly Reports
08/01/2013 08/01/2013 8-K Special Events
07/25/2013 07/25/2013 8-K Special Events
06/26/2013 06/26/2013 8-K Special Events
06/14/2013 06/10/2013 8-K Special Events
06/10/2013 N/A S-8 Registration Statement
06/07/2013 06/07/2013 8-K Special Events
05/09/2013 03/31/2013 10-Q Quarterly Reports
05/02/2013 05/02/2013 8-K Special Events
04/29/2013 06/10/2013 DEF 14A Proxy Statement
04/10/2013 N/A SC 13G/A Institutional Ownership *
04/05/2013 04/05/2013 8-K Special Events
04/01/2013 04/01/2013 8-K Special Events
03/04/2013 03/04/2013 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
ARNA Arena Pharmaceuticals Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=ARNA&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/ARNA/quote
Stock Chart http://www.otcmarkets.com/stock/ARNA/chart
Company Info http://www.otcmarkets.com/stock/ARNA/company-info
Recent News http://www.otcmarkets.com/stock/ARNA/news
Financials http://www.otcmarkets.com/stock/ARNA/financials
Filings and Disclosure http://www.otcmarkets.com/stock/ARNA/filings
Short Sales http://www.otcmarkets.com/stock/ARNA/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/ARNA/insider-transactions
Research Reports http://www.otcmarkets.com/stock/ARNA/research
Summary http://finance.yahoo.com/q?s=ARNA
Historical Prices http://finance.yahoo.com/q/hp?s=ARNA+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=ARNA
Basic Chart http://finance.yahoo.com/q/bc?s=ARNA+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=ARNA+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=ARNA+Headlines
Press Releases http://finance.yahoo.com/q/p?s=ARNA+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=ARNA+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=ARNA+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=ARNA+Industry
Major Holders http://finance.yahoo.com/q/mh?s=ARNA+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=ARNA+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=ARNA+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=ARNA
Balance Sheet http://finance.yahoo.com/q/bs?s=ARNA
Cash Flow http://finance.yahoo.com/q/cf?s=ARNA+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/ARNA
Market Watch http://www.marketwatch.com/investing/stock/ARNA
Bloomberg http://www.bloomberg.com/quote/ARNA:US
Morningstar http://quotes.morningstar.com/stock/s?t=ARNA
Bussinessweek http://investing.businessweek.com/research/st...icker=ARNA
Barchart http://www.barchart.com/quotes/stocks/ARNA
OTC Short Report http://otcshortreport.com/index.php?index=ARNA
Investopedia http://www.investopedia.com/markets/stocks/ARNA/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on discovery, development and commercialization of drugs in the therapeutic areas such as cardiovascular, central nervous system, inflammatory and metabolic diseases. Its product pipeline includes Lorcaserin, APD811, APD334, APD371, GPR119 agonists, temanogrel and nelotanserin. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.
ARNA Last Price: 6.55
Last Updated: November 29, 2013 2:14 PM EST
ARNA Stock Message Board and Forum http://investorshangout.com/search?q=ARNA&...mp;yt0=Go!
Arena Pharmaceuticals Inc. ARNA Officers and Executives
Name Age Officer Since Title
Mr. Jack Lief 67 1997 Chairman, President & Chief Executive Officer
Dr. Craig M. Audet 49 2011 SVP-Operations & Head-Global Regulatory Affairs
Mr. Robert E. Hoffman 47 1997 Chief Financial Officer & Vice President
Dr. William R. Shanahan 64 2004 Chief Medical Officer & Senior Vice President
Dr. Dominic P. Behan 49 1997 Chief Scientific Officer, Executive Director & EVP
Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego, California 92121
Phone
1 8584537200
Industry
Biotechnology
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$27.59M
Net Income
$-85.48M
2012 Sales Growth
116.9%
Employees
293.00
Annual Report Below for ARNA
Arena Pharmaceuticals Inc. ARNA Recent Headlines
MarketWatch News on ARNA
Arena shares surge as marketer doubles sales force for diet drug 11:41 a.m. Oct. 15, 2013 - Russ Britt
Obesity drug makers jockey for position as analysts praise Vivus 12:06 p.m. Oct. 3, 2013 - Russ Britt
Hedge funds are buying these stocks right now 1:46 p.m. July 23, 2013 - Insider Monkey
5 stocks insiders are buying 1:52 p.m. June 7, 2013 - Insider Monkey
6 gut checks before the stock market's opening bell 6:47 a.m. March 7, 2013 - Shawn Langlois
Stocks to watch Monday: Transocean, Stratasys 9:22 a.m. March 4, 2013 - Sue Chang
Arena Pharmaceuticals down 7.4% in premarket 9:11 a.m. Jan. 22, 2013 - Steve Gelsi
What 2012’s winners and losers say about 2013 6:00 a.m. Dec. 14, 2012 - Howard Gold
6 gut checks before the stock market's opening bell 6:50 a.m. Dec. 12, 2012 - Shawn Langlois
4 charts challenging resistance 7:06 a.m. Oct. 16, 2012 - The Trading Deck
Vivus sees EU regulators rejecting diet drug 12:16 p.m. Sept. 21, 2012 - MarketWatch.com
Vivus falls 11% on EU drug approval update 11:07 a.m. Sept. 21, 2012 - Val Brickates Kennedy
Arena rises as Vivus sees anti-obesity setback 7:49 a.m. Sept. 21, 2012 - Greg Morcroft
Vivus says Europe likely to reject obesity drug 7:33 a.m. Sept. 21, 2012 - MarketWatch.com
Orexigen soars 19% on analyst buy rating 12:46 p.m. Sept. 6, 2012 - Val Brickates Kennedy
Arena jumps 12% amid takeover speculation 1:55 p.m. Aug. 14, 2012 - Val Brickates Kennedy
Arena trips Nasdaq short-sale circuit breaker 3:01 p.m. Aug. 1, 2012 - Val Brickates Kennedy
Arena Pharma share drop trips short-sale limit 2:16 p.m. Aug. 1, 2012 - Laura Mandaro
Eisai gears up for launch of Arena's diet drug 9:32 a.m. July 30, 2012 - Val Brickates Kennedy
Apple, Arena active; Lumber Liquidators at new high 9:06 a.m. July 25, 2012 - blogs.marketwatch.com
Contrave Data is Positive for Orexigen's Other Weight-Loss Candidate - Analyst 1:08 p.m. Nov. 27, 2013 - Seeking Alpha
ARNA January 2014 Options Begin Trading 10:53 a.m. Nov. 27, 2013 - TheStreet.com
Orexigen Sees Positive Interim Results On Drug Study 1:18 a.m. Nov. 26, 2013 - Seeking Alpha
Arena's Belviq Prescription Data - Week 23 1:28 p.m. Nov. 25, 2013 - Seeking Alpha
Orexigen to Seek FDA Approval for Contrave 12:43 p.m. Nov. 25, 2013 - WSJ.com
3 Monday Morning Biotech Movers 12:15 p.m. Nov. 25, 2013 - Wall St. Cheat Sheet
Investors Put Greater Weight Behind Orexigen Than Arena, Vivus 12:10 p.m. Nov. 25, 2013 - TheStreet.com
Orexigen Weight-Loss Pill Passes Safety Hurdle 7:41 a.m. Nov. 25, 2013 - TheStreet.com
December 27th Options Now Available For Arena Pharmaceuticals (ARNA) 11:02 a.m. Nov. 21, 2013 - TheStreet.com
Interesting ARNA Put And Call Options For July 2014 12:02 p.m. Nov. 19, 2013 - TheStreet.com
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results 1:11 p.m. Nov. 16, 2013 - GuruFocus.com
Apple’s Smartphone Share Declines, JPMorgan’s Chinese Debacle, and 3 More Hot Stocks 1:08 p.m. Nov. 15, 2013 - Wall St. Cheat Sheet
Benzinga's Top #PreMarket Gainers 7:16 a.m. Nov. 15, 2013 - benzinga.com
ARNA December 13th Options Begin Trading 10:53 a.m. Nov. 14, 2013 - TheStreet.com
Arena Expands Marketing Of Obesity Drug To Help Shrink Waistlines 5:00 p.m. Nov. 12, 2013 - TheStreet.com
10-Q: ARENA PHARMACEUTICALS INC 3:52 p.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Jim Cramer: Buy Apple, Sell AMD, and 2 More Stock Picks 12:05 p.m. Nov. 12, 2013 - Wall St. Cheat Sheet
Arena Pharmaceuticals (ARNA) Worth a Look: Stock Surges 10.6% - Tale of the Tape 8:44 a.m. Nov. 12, 2013 - Zacks.com
Cramer's Lightning Round - Don't Back Away From The Hottest Stock In The Universe (11/11/13) 6:03 a.m. Nov. 12, 2013 - Seeking Alpha
'Mad Money' Lightning Round: 6:00 a.m. Nov. 12, 2013 - TheStreet.com
Press Releases on ARNA
Promising Partnerships, Stock Price Updates and Participation in Upcoming Healthcare Conferences - Research Report on Quest Diagnostics, Cigna, Arena, Theravance, and Volcano 8:00 a.m. Today - PR Newswire
Arena Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference 8:00 a.m. Nov. 27, 2013 - PR Newswire
Trend Analysis Scan: Synovus Financial, Arena Pharmaceuticals, Facebook Inc, J.C. Penney Company, Citigroup 8:49 a.m. Nov. 26, 2013 - PR Newswire
Early Briefing and Review: Arena Pharma Inc., Geron Corp., Incyte Corp., and Spectrum Pharma Inc. 1:31 p.m. Nov. 22, 2013 - PR Newswire
Health Care Initiatives, Clinical Data Presentations, Public Offerings, Contract Extensions and Publication of Pre-Clinical Study - Research Report on Cigna, Arena, Synta, Healthways, and Catalyst 8:00 a.m. Nov. 21, 2013 - PR Newswire
BELVIQ® (lorcaserin HCl) CIV Data to be Presented at American Heart Association 2013 Scientific Sessions 8:00 a.m. Nov. 18, 2013 - PR Newswire
BELVIQ® (lorcaserin HCl) CIV Data Featured in Five Abstracts to be Presented at ObesityWeek(SM) 2013 4:05 p.m. Nov. 13, 2013 - PR Newswire
Biotechnology Companies' Quarterly Results - Research Report on Geron, Santarus, Merrimack, Clovis, and Arena 8:00 a.m. Nov. 12, 2013 - PR Newswire
GOGO, CLDX, VPHM and ARNA Added to NASDAQ Active Stock Watch List at EPR 10:14 a.m. Nov. 11, 2013 - ACCESSWIRE
TrendingWallStreet.com Initiates Research on EGY, GLER, PGLO, and ARNA 12:16 a.m. Nov. 11, 2013 - ACCESSWIRE
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results 4:10 p.m. Nov. 7, 2013 - PR Newswire
Arena Pharmaceuticals and Eisai Expand Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) to Include Most Countries Worldwide 4:02 p.m. Nov. 7, 2013 - PR Newswire
FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on Pfizer, Mettler-Toledo, Arena, Wright Medical, and Ophthotech 8:00 a.m. Nov. 7, 2013 - PR Newswire
Must Watch Stock News: Arena Pharmaceuticals, Hewlett-Packard Company, Resorts International, Alpha Natural Resources, Chevron Corporation 1:56 p.m. Nov. 4, 2013 - PR Newswire
Pre-Market Review: Arena Pharma Inc., Geron Corp., Incyte Corp. Ltd, and Spectrum Pharma Inc. 9:00 a.m. Oct. 31, 2013 - PR Newswire
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7 8:00 a.m. Oct. 30, 2013 - PR Newswire
Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics, Halozyme, Insmed, and Omeros 8:00 a.m. Oct. 21, 2013 - PR Newswire
Arena Pharmaceuticals Reports That Eisai Will Double BELVIQ® (lorcaserin HCl) CIV Sales Force by December 9:03 a.m. Oct. 15, 2013 - PR Newswire
Early Briefing and Review: Arena Pharma Inc., Spectrum Pharma Inc., Incyte Corp. Ltd., and Geron Corp. 9:26 a.m. Oct. 8, 2013 - PR Newswire
Drug Approvals, Data Presentations, Conferences, Increased Funding, and Merger Agreements - Research Report on Theravance, Arena, Exelixis, Verenium, and Enanta 8:00 a.m. Sept. 25, 2013 - PR Newswire
Valuation
P/E Current
-14.31
P/E Ratio (with extraordinary items)
-81.48
Price to Sales Ratio
64.26
Price to Book Ratio
19.89
Enterprise Value to EBITDA
-25.27
Enterprise Value to Sales
15.59
Total Debt to Enterprise Value
0.04
Efficiency
Revenue/Employee
0.09
Income Per Employee
-0.29
Receivables Turnover
8.95
Total Asset Turnover
0.13
Liquidity
Current Ratio
5.72
Quick Ratio
5.52
Cash Ratio
5.22
Profitability
Gross Margin
-34.55
Operating Margin
-207.03
Pretax Margin
-309.85
Net Margin
-309.85
Return on Assets
-40.87
Return on Equity
-156.55
Return on Total Capital
-62.36
Return on Invested Capital
-63.05
Capital Structure
Total Debt to Total Equity
75.49
Total Debt to Total Capital
43.02
Total Debt to Total Assets
28.51
Long-Term Debt to Equity
73.80
Long-Term Debt to Total Capital
42.05
Arena Pharmaceuticals Inc. ARNA Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 9.81M 10.39M 16.61M 12.72M 27.59M
Cost of Goods Sold (COGS) incl. D&A 22.49M 21.06M 19.97M 19.22M 37.12M
COGS excluding D&A 8.52M 6.54M 7.41M 8.1M 27.37M
Depreciation & Amortization Expense 13.98M 14.53M 12.55M 11.12M 9.75M
Depreciation 11.67M 11.02M 10.39M 10.13M 9.06M
Amortization of Intangibles 2.31M 3.51M 2.16M 997,000 691,000
Gross Income (12.69M) (10.68M) (3.35M) (6.51M) (9.53M)
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 223.24M 124.39M 93M 72.83M 47.58M
Research & Development 204.37M 110.16M 75.46M 58.71M 30.41M
Other SG&A 18.87M 14.23M 17.54M 14.12M 17.17M
Other Operating Expense 0 0 0 0 0
Unusual Expense 3.84M 385,000 7.98M 13.93M 19.76M
EBIT after Unusual Expense (3.84M) (385,000) (7.98M) (13.93M) (19.76M)
Non Operating Income/Expense (1.1M) 273,000 1.02M (1.77M) 400,000
Non-Operating Interest Income 8.97M 689,000 469,000 117,000 119,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 5.68M 18.72M 21.68M 14.31M 9.12M
Gross Interest Expense 5.68M 18.72M 21.68M 14.31M 9.12M
Interest Capitalized 0 0 0 0 0
Pretax Income (237.57M) (153.2M) (124.53M) (109.22M) (85.48M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 -
Income Tax - Current Foreign 0 0 0 0 -
Income Tax - Deferred Domestic 0 0 0 0 -
Income Tax - Deferred Foreign 0 0 0 0 -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (237.57M) (153.2M) (124.53M) (109.22M) (85.48M)
Minority Interest Expense 0 0 0 0 0
Net Income (237.57M) (153.2M) (124.53M) (109.22M) (85.48M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (237.57M) (153.2M) (124.53M) (109.22M) (85.48M)
Preferred Dividends 1.91M 0 0 2.26M 2.82M
Net Income Available to Common (239.49M) (153.2M) (124.53M) (111.48M) (88.3M)
EPS (Basic) (3.24) (1.82) (1.14) (0.80) (0.45)
Basic Shares Outstanding 73.84M 84.34M 109.57M 139.17M 196.52M
EPS (Diluted) (3.24) (1.82) (1.14) (0.80) (0.45)
Diluted Shares Outstanding 73.84M 84.34M 109.57M 139.17M 196.52M
EBITDA (221.95M) (120.54M) (83.8M) (68.21M) (47.37M)
Arena Pharmaceuticals Inc. ARNA Filings
SEC Filings for Arena Pharmaceuticals Inc.
Filing Date Document Date Type Category Amended
11/12/2013 09/30/2013 10-Q Quarterly Reports
11/08/2013 11/07/2013 8-K Special Events
11/07/2013 11/07/2013 8-K Special Events
10/15/2013 10/15/2013 8-K Special Events
08/29/2013 08/28/2013 8-K Special Events
08/28/2013 08/28/2013 8-K Special Events
08/05/2013 06/30/2013 10-Q Quarterly Reports
08/01/2013 08/01/2013 8-K Special Events
07/25/2013 07/25/2013 8-K Special Events
06/26/2013 06/26/2013 8-K Special Events
06/14/2013 06/10/2013 8-K Special Events
06/10/2013 N/A S-8 Registration Statement
06/07/2013 06/07/2013 8-K Special Events
05/09/2013 03/31/2013 10-Q Quarterly Reports
05/02/2013 05/02/2013 8-K Special Events
04/29/2013 06/10/2013 DEF 14A Proxy Statement
04/10/2013 N/A SC 13G/A Institutional Ownership *
04/05/2013 04/05/2013 8-K Special Events
04/01/2013 04/01/2013 8-K Special Events
03/04/2013 03/04/2013 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
ARNA Arena Pharmaceuticals Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=ARNA&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/ARNA/quote
Stock Chart http://www.otcmarkets.com/stock/ARNA/chart
Company Info http://www.otcmarkets.com/stock/ARNA/company-info
Recent News http://www.otcmarkets.com/stock/ARNA/news
Financials http://www.otcmarkets.com/stock/ARNA/financials
Filings and Disclosure http://www.otcmarkets.com/stock/ARNA/filings
Short Sales http://www.otcmarkets.com/stock/ARNA/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/ARNA/insider-transactions
Research Reports http://www.otcmarkets.com/stock/ARNA/research
Summary http://finance.yahoo.com/q?s=ARNA
Historical Prices http://finance.yahoo.com/q/hp?s=ARNA+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=ARNA
Basic Chart http://finance.yahoo.com/q/bc?s=ARNA+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=ARNA+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=ARNA+Headlines
Press Releases http://finance.yahoo.com/q/p?s=ARNA+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=ARNA+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=ARNA+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=ARNA+Industry
Major Holders http://finance.yahoo.com/q/mh?s=ARNA+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=ARNA+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=ARNA+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=ARNA
Balance Sheet http://finance.yahoo.com/q/bs?s=ARNA
Cash Flow http://finance.yahoo.com/q/cf?s=ARNA+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/ARNA
Market Watch http://www.marketwatch.com/investing/stock/ARNA
Bloomberg http://www.bloomberg.com/quote/ARNA:US
Morningstar http://quotes.morningstar.com/stock/s?t=ARNA
Bussinessweek http://investing.businessweek.com/research/st...icker=ARNA
Barchart http://www.barchart.com/quotes/stocks/ARNA
OTC Short Report http://otcshortreport.com/index.php?index=ARNA
Investopedia http://www.investopedia.com/markets/stocks/ARNA/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
